An Imaging-related Clinical Trial Endpoint

Ellipsoid zone integrity is an OCT biomarker in dry age-related macular degeneration that the FDA now supports as an approvable clinical trial endpoint.

By: Jim Gallagher, senior managing editor

Retinal Physician January 1, 2025 Vol 21, Issue January/February 2025

Clinical Report: An Imaging-related Clinical Trial Endpoint

Overview

Ellipsoid zone integrity is now recognized by the FDA as an approvable endpoint specifically for clinical trials in dry age-related macular degeneration (AMD). This imaging biomarker can predict disease progression and may help identify patients who would benefit from new treatments.

Background

The identification of reliable clinical trial endpoints is crucial for the development of effective therapies in dry AMD. Imaging biomarkers, particularly those derived from optical coherence tomography (OCT), offer a non-invasive means to assess disease progression and treatment efficacy. The FDA's endorsement of ellipsoid zone integrity as a trial endpoint marks a significant advancement in the regulatory landscape for AMD treatments, emphasizing the role of OCT-derived biomarkers in improving clinical trial design.

Data Highlights

No numerical data available in the article.

Key Findings

Ellipsoid zone (EZ) integrity is now an FDA-approved endpoint for dry AMD clinical trials.
Measurement of the distance between the ellipsoid zone and retinal pigment epithelium (RPE) is critical for assessing EZ integrity.
Partial EZ attenuation is defined as EZ-RPE thickness ≤20 µm.
Machine learning segmentation methods show consistency comparable to manual methods for assessing EZ integrity, enhancing the reliability of OCT assessments.
Reflectivity of the ellipsoid zone is linked to visual function and disease progression.
Standardization of OCT-EZ measures is recommended for reproducibility in clinical trials.

Clinical Implications

Clinicians should consider the use of ellipsoid zone integrity as a key biomarker in assessing treatment outcomes for patients with dry AMD. The integration of machine learning tools may enhance the accuracy and efficiency of OCT assessments in clinical settings, potentially leading to better patient management.

Conclusion

The FDA's recognition of ellipsoid zone integrity as an approvable endpoint represents a pivotal step in the advancement of clinical trials for dry AMD. This development underscores the importance of imaging biomarkers in guiding treatment strategies and improving patient outcomes.

PentaVision

Retinal Physician